Richter Syndrome - 20 Studies Found Completed : VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders : Leukemia Lymphoma : 2006-03-15 : Drug: laromustine Completed : Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL : Leukemia : 2007-03-23 : Drug: Cytarabine 1 g/m^2 given Active, not recruiting : ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia : Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma : 2014-01-06 : Drug: acalabrutinib Recruiting : Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL or Richter's Transformation : Chronic Lymphocytic Leukemia : 2015-08-24 : Drug: Pembrolizumab IV immunot Completed : Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT) : Chronic Lymphocytic Leukemia : 2006-03-29 : Biological: rituximab Drug: cyclophosphami Withdrawn : Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation : Prolymphocytic Leukemia Recurrent Mantle Cell Lymphoma Rec : 2014-11-04 : Drug: sotrastaurin acetate Giv Recruiting : Registry of the German CLL Study Group : CLL SLL HCL : 2015-02-26 Recruiting : Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL : Contiguous Stage II Small Lymphocytic Lymphoma Noncontiguous Stage II Small Lymphocytic Lymp : 2013-12-03 : Biological: MOR00208 Given by Completed : Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL : B-cell Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Drug: PCI-32765 420 mg PO dail Active, not recruiting : ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies : Non-hodgkin Lymphoma Multiple Myeloma Hodgkin Lymphoma : 2015-02-07 : Drug: Acalabrutinib oral <<< Previous